Studying Why Some People With Multiple Sclerosis Have a Harder Course
Studies blood cells from early multiple sclerosis patients to compare aggressive and non-aggressive disease.
Plain-language title generated from the registry record
Registry title: From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Key facts
- Where
- Nantes, FranceSee the site
Where in France
- Nantes University HospitalNantes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT04873492
- Record updated
- 19 March 2026
- Original description
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controlsRead full original descriptionShow less
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Inclusion: Common criteria for retrospective MS patients:; Patients aged 18 years or older; Clinical isolated syndrome (CIS) with or without dissemination in space; Patients affiliated to an appropriate health insurance; Criteria for Aggressive MS group; Start of a 2nd line therapy within the two years following the CIS; Criteria for Non aggressive MS group; No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or; Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years; Have a minimum of least 2 years of follow-up; Healthy volunteers; Aged 18 years or older; No history of clinically isolated syndrome or MS; Pairing criteria :; Age +/- 5 years; Sex; Prospective MS Patients; Patients aged 18 years or older; Clinical isolated syndrome (CIS) with or without dissemination in space; Patients affiliated to an appropriate health insurance.
Exclusion: Immunosuppressive drug at the time of blood collection; Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample; Ongoing participation to a another study; Refusal to genetic analyses; Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard); Pregnancy.